ZAR1 and neoplasm: In primary tumour samples from SCLC, the ZAR1 promoter was methylated in 5 out of 23 (22%) and in NSCLC, 16 out of 21 (76%) (Fig. 3 and Additional file 2: Table S1 and Additional file 3: Table S2).